Table 1.
Comparison of demographics and hormonal concentrations of type 1 and type 2 diabetic patients
| Type 2 diabetes | Type 1 diabetes | P | |
|---|---|---|---|
| n | 24 | 38 | |
| Age (years) | 27.87 ± 0.97 | 26.45 ± 0.89 | 0.37 |
| BMI (kg/m2) | 38.55 ± 2.04 | 27.41 ± 1.18 | <0.001 |
| Total testosterone (nmol/l) | 11.14 ± 0.99 | 22.89 ± 1.23 | <0.001 |
| Free testosterone (nmol/l) | 0.296 ± 0.022 | 0.489 ± 0.030 | <0.001 |
| % hypogonadal | 33% | 8% | 0.02 |
| SHBG (nmol/l) | 19.63 ± 2.41 | 36.43 ± 2.28 | <0.001 |
| LH (IU/l) | 3.5 ± 0.4 | 3.79 ± 0.44 | 0.58 |
| FSH (IU/l) | 3.46 ± 0.43 | 4.54 ± 0.87 | 0.61 |
| Prolactin (mcg/l) | 6.97 ± 0.65 | 7.44 ± 0.59 | 0.57 |
| A1C (%) | 7.09 ± 0.42 | 7.73 ± 0.22 | 0.17 |
| Caucasian (%) | 50 | 92 | <0.001 |
| African American (%) | 25 | 5 | <0.001 |
| Hispanic (%) | 21 | 0 | <0.001 |
| Asian (%) | 4 | 3 | 0.61 |
| Insulin use | 57 | 100 | <0.001 |
| Mean insulin dose (units) | 72 ± 18 | 60 ± 4 | 0.96 |
| Exenatide use [% (dose)] | 21% (6.7 ± 1.7 μg) | 3% (5 ± 0 μg) | <0.001 |
| Metformin use [% (dose)] | 86% (1.6 ± 0.2 g) | 7% (2 ± 0 g) | <0.001 |
| Sulfonylurea use [% (dose)] | 64% (9 ± 1.4 mg) | 0 | <0.001 |
| Thiazolidinedione use (%) | 21 | 0 | <0.001 |
| C-peptide (ng/ml) | 2.13 ± 0.45 | 0.36 ± 0.13 | 0.001 |
Data are means ± SE or percent, unless otherwise indicated.